CoChat

Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights

Open access
Dienstmann, Rodrigo, Elez, Elena, Argiles, Guillem, Matos, Ignacio, Sanz‐Garcia, Enrique, Ortiz, Carolina, Macarulla, Teresa, Capdevila, Jaume, Alsina, Maria, Sauri, Tamara, Verdaguer, Helena, Vilaro, Marta, Ruiz‐Pace, Fiorella, Viaplana, Cristina, Garcia, Ariadna, Landolfi, Stefania, Palmer, Hector G., Nuciforo, Paolo, Rodon, Jordi, Vivancos, Ana, Tabernero, Josep · 2017 · Molecular Oncology
Cited by 56

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Sequencing of tumors is now routine and guides personalized cancer therapy. Mutant allele fractions (MAF s, or the ‘mutation dose’) of a driver gene may reveal the genomic structure of tumors and influence response to targeted therapies. We performed a comprehensive analysis of MAF s of driver alterations in unpaired primary and metastatic colorectal cancer (CRC) at our institution from 2010 to 2015 and studied their potential clinical relevance. Of 763 CRC samples, 622 had detailed annotation on overall survival in the metastatic setting (OS met) and 89 received targeted agents matched to KRAS (MEK inhibitors), BRAF (BRAF inhibitors), or PIK 3 CA mutations (PI 3K pathway inhibitors). MAF s of each variant were normalized for tumor purity in the sample (adj MAF s). We found lower adj MAF s for BRAFV600E and PIK 3 CA than for KRAS, NRAS, and BRAF non‐V600 variants. TP 53 and BRAFV600E adj MAF s were higher in metastases as compared to primary tumors, and high KRAS adj MAF s were found in CRC metastases of patients with KRAS wild‐type primary tumors previously exposed to EGFR antibodies. Patients with RAS‐ or BRAFV600E‐mutated tumors, irrespective of adj MAF s, had worse OS met. There was no significant association between adj MAF s and time to progression on targeted therapies matched to KRAS, BRAF, or PIK 3 CA mutations, potentially related to the limited antitumor activity of the employed drugs (overall response rate of 4.5%). In conclusion, the lower BRAFV600E and PIK 3 CA adj MAF s in subsets of primary CRC tumors indicate subclonality of these driver genes. Differences in adj MAF s between metastases and primary tumors suggest that approved therapies may result in selection of BRAFV600E‐ and KRAS‐resistant clones and an increase in genomic heterogeneity with acquired TP 53 alterations. Despite significant differences in prognosis according to mutations in driver oncogenes, adj MAF s levels did not impact on survival and did not help predict benefit with matched targeted agents in the metastatic setting.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/1878-0261.12099

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 56

Metadata

Authors
Dienstmann, R., Elez, E., Argiles, G., Matos, I., Sanz‐Garcia, E., Ortiz, C., Macarulla, T., Capdevila, J., Alsina, M., Sauri, T., Verdaguer, H., Vilaro, M., Ruiz‐Pace, F., Viaplana, C., Garcia, A., Landolfi, S., Palmer, H. G., Nuciforo, P., Rodon, J., Vivancos, A., & Tabernero, J.
Venue
Molecular Oncology
Publisher
Wiley
Published
2017-07-20
Volume
11
Issue
9
Pages
1263-1272
ISSN
  • 1574-7891 (ISSN-L)
  • 1878-0261
OpenAlex
W2626175572
Cited by
56
References
2
FWCI
2.05
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.